Results 31 to 40 of about 163,730 (308)

Cancer vaccines and immunotherapy [PDF]

British Medical Bulletin, 2002
It is now clear that many human tumour antigens can be recognised by the immune system. These tumour antigens can be classified into several groups including cancer-testis, differentiation, tissue specific, over-expressed, and viral-associated antigens. In many cases, there is a known molecular basis of carcinogenesis which provides the explanation for
Said, Dermime, Anne, Armstrong, Robert E, Hawkins, Peter L, Stern   +3 more
openaire   +2 more sources

Advances in mRNA-Based Cancer Vaccines

, 2023
Cancer is a leading cause of death worldwide, accounting for millions of deaths every year. Immunotherapy is a groundbreaking approach for treating cancer through harnessing the power of the immune system to target and eliminate cancer cells.
Ling Ni
core   +1 more source

Adaptive T cell responses induced by oncolytic Herpes Simplex Virus-granulocyte macrophage-colony-stimulating factor therapy expanded by dendritic cell and cytokine-induced killer cell adoptive therapy

OncoImmunology, 2017
Purpose: Although local oncolytic viral therapy (OVT) may enhance tumor lysis, antigen release, and adaptive immune responses, systemic antitumor responses post-therapy are limited. Adoptive immunotherapy with autologous dendritic cells (DC) and cytokine-
Jun Ren, William R. Gwin, Xinna Zhou, Xiaoli Wang, Hongyan Huang, Ni Jiang, Lei Zhou, Pankaj Agarwal, Amy Hobeika, Erika Crosby, Zachary C. Hartman, Michael A. Morse, Kevin H. Eng, H. Kim Lyerly   +13 more
doaj   +1 more source

Cancer vaccines in the clinic

Bioengineering & Translational Medicine, 2023
AbstractVaccines are an important tool in the rapidly evolving repertoire of immunotherapies in oncology. Although cancer vaccines have been investigated for over 30 years, very few have achieved meaningful clinical success. However, recent advances in areas such antigen identification, formulation development and manufacturing, combination therapy ...
Morgan E. Janes, Alexander P. Gottlieb, Kyung Soo Park, Zongmin Zhao, Samir Mitragotri   +4 more
openaire   +3 more sources

Complete Rescue of HTLV-1_p12KO Infectivity by Depletion of Monocytes Together with NK and CD8⁺ T Cells

Pathogens
The transient depletion of monocytes alone prior to exposure of macaques to HTLV-1 enhances both HTLV-1WT (wild type) and HTLV-1p12KO (Orf-1 knockout) infectivity, but seroconversion to either virus is not sustained over time, suggesting a progressive ...
Anna Gutowska, Sarkis Sarkis, Mohammad Arif Rahman, Katherine C. Goldfarbmuren, Ramona Moles, Massimiliano Bissa, Melvin Doster, Robyn Washington-Parks, Katherine McKinnon, Isabela Silva de Castro, Luca Schifanella, Genoveffa Franchini, Cynthia A. Pise-Masison   +12 more
doaj   +1 more source

Cancer vaccines

BMJ, 2015
Cancer vaccines are designed to promote tumor specific immune responses, particularly cytotoxic CD8 positive T cells that are specific to tumor antigens. The earliest vaccines, which were developed in 1994-95, tested non-mutated, shared tumor associated antigens that had been shown to be immunogenic and capable of inducing clinical responses in a ...
openaire   +3 more sources

Therapeutic cancer vaccines: Where do we stand?

Journal of Integrative Medicine and Research, 2023
Vaccines and immunotherapy have transformed the treatment modalities and prevention of several diseases including malignancy. Vaccines for infectious diseases have been in use for many decades, but very few cancer vaccines are approved for human use ...
Rajlaxmi Sarangi, Srikrushna Mahapatra, Jyotirmayee Bahinipati, Sumit Jhajharia, Tapaswini Pradhan   +4 more
doaj   +1 more source

Guidance for peptide vaccines for the treatment of cancer

, 2014
Recent progress in fundamental understanding of tumor immunology has opened a new avenue of cancer vaccines. Currently, the development of new cancer vaccines is a global topic and has attracted attention as one of the most important issues in Japan ...
Junji Furuse, Yasuo Ohashi, Yamaue, Hiroki, Atsushi Otsu, Kazuto Nishio, Furuse, Junji, Hironobu Minami, Nakamura, Yusuke, Yoshiyuki Yamaguchi, Hiroyuki Suzuki, Tsunoda, Takuya, Yusuke Nakamura, Suzuki, Hiroyuki, Shimazawa, Rumiko, Hayashi, Yuzo, Takuji Okusaka, Ohashi, Yasuo, Okuno, Kiyotaka, Nishio, Kazuto, Rumiko Shimazawa, Otsu, Atsushi, Yuzo Hayashi, Tomoaki Fujioka, Fujioka, Tomoaki, Minami, Hironobu, Yamaguchi, Yoshiyuki, Takuya Tsunoda, Okusaka, Takuji, Hiroki Yamaue, Kiyotaka Okuno   +29 more
core   +2 more sources

Mimicking Pathogens to Augment the Potency of Liposomal Cancer Vaccines [PDF]

, 2021
Liposomes have emerged as interesting vehicles in cancer vaccination strategies as their composition enables the inclusion of both hydrophilic and hydrophobic antigens and adjuvants.
Cornelus F. van Nostrum, Nijen Twilhaar, Maarten K, den Haan, Joke M M, Joke M. M. den Haan, Maarten K. Nijen Twilhaar, Gert Storm, Den Haan, Joke M.M., van Nostrum, Cornelus F, Twilhaar, Maarten K.Nijen, Czentner, Lucas, Storm, Gert, van Nostrum, Cornelus F., Lucas Czentner   +12 more
core   +1 more source

Epitope-based vaccines for cancer

, 2011
INTRODUCTION Epitope-based cancer vaccination, comprised of minimal immunogenic portions of a cancer antigen, represents an immunotherapy that combines target specifi city with long-lasting immunity. Advances in epitope identifi cation and immunogenicity

core   +1 more source